Zhejiang Int'l Group Co

Zhejiang Int'l Group Co Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Zhejiang Int'l Group Co (000411.SZ) as of Oct 21, 2026 is -20.36. In the previous year, Cash Conversion Cycle (CCC) was 50.12 — a change of -140.62% (lower).

Cash Conversion Cycle

-20.36

YoY

-140.62%

Last updated:

Cash Conversion Cycle (CCC) of Zhejiang Int'l Group Co is 2025 -20.36 . Cash Conversion Cycle (CCC) of Zhejiang Int'l Group Co was 2024 50.12 . It decreases by -140.62% lower compared to the previous year.

The Zhejiang Int'l Group Co Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
48.83 CNY
Jan 1, 2019
40.88 CNY
Jan 1, 2020
45.55 CNY
Jan 1, 2021
62.51 CNY
Jan 1, 2022
56.28 CNY
Jan 1, 2023
48.00 CNY
Jan 1, 2024
50.12 CNY
Jan 1, 2025
-20.36 CNY
The Zhejiang Int'l Group Co Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-20.36-140.62%
50.12+4.41%
48.00-14.72%
56.28-9.96%
62.51+37.25%
45.55+11.42%
40.88-16.29%
48.83+54.82%
31.54+12.63%
28.00+8.48%
25.81+1.14%
25.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

Cash Conversion Cycle (CCC) of Zhejiang Int'l Group Co is -20.36 in 2025.

Cash Conversion Cycle (CCC) of Zhejiang Int'l Group Co changed from 50.12 to -20.36, representing a -140.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Zhejiang Int'l Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co